

CLAIMS

WHAT IS CLAIMED IS:

1. An isolated nucleic acid molecule comprising a polynucleotide having a nucleotide sequence at least 95% identical to a sequence selected from the group
5 consisting of:

(a) a polynucleotide fragment of SEQ ID NO:1 or a polynucleotide fragment of the cDNA sequence included in ATCC Deposit No: PTA-2766, which is hybridizable to SEQ ID NO:1;

- 10 (b) a polynucleotide encoding a polypeptide fragment of SEQ ID NO:2 or a polypeptide fragment encoded by the cDNA sequence included in ATCC Deposit No: PTA-2766, which is hybridizable to SEQ ID NO:1;

(c) a polynucleotide encoding a polypeptide domain of SEQ ID NO:2 or a polypeptide domain encoded by the cDNA sequence included in ATCC Deposit No: PTA-2766, which is hybridizable to SEQ ID NO:1;

- 15 (d) a polynucleotide encoding a polypeptide epitope of SEQ ID NO:2 or a polypeptide epitope encoded by the cDNA sequence included in ATCC Deposit No: PTA-2766, which is hybridizable to SEQ ID NO:1;

- (e) a polynucleotide encoding a polypeptide of SEQ ID NO:2 or the cDNA sequence included in ATCC Deposit No: PTA-2766, which is hybridizable to SEQ ID
20 NO:1, having biological activity;

(f) a polynucleotide which is a variant of SEQ ID NO:1;

(g) a polynucleotide which is an allelic variant of SEQ ID NO:1;

- (h) an isolated polynucleotide comprising nucleotides 518 to 1504 of SEQ ID NO:1, wherein said nucleotides encode a polypeptide of SEQ ID NO:2 minus the start
25 codon;

(i) an isolated polynucleotide comprising nucleotides 515 to 1504 of SEQ ID NO:1, wherein said nucleotides encode a polypeptide of SEQ ID NO:2 including the start codon;

- 30 (j) a polynucleotide which represents the complimentary sequence (antisense) of SEQ ID NO:1; and

(k) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(j), wherein said polynucleotide does not

hybridize under stringent conditions to a nucleic acid molecule having a nucleotide sequence of only A residues or of only T residues.

2. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises a nucleotide sequence encoding a G-protein coupled receptor protein.

3. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises a nucleotide sequence encoding the sequence identified as SEQ ID NO:2 or the polypeptide encoded by the cDNA sequence included in ATCC Deposit No: PTA-2766, which is hybridizable to SEQ ID NO:1.

4. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises the entire nucleotide sequence of SEQ ID NO:1 or the cDNA sequence included in ATCC Deposit No: PTA-2766, which is hybridizable to SEQ ID NO:1.

5. The isolated nucleic acid molecule of claim 2, wherein the nucleotide sequence comprises sequential nucleotide deletions from either the C-terminus or the N-terminus.

6. The isolated nucleic acid molecule of claim 3, wherein the nucleotide sequence comprises sequential nucleotide deletions from either the C-terminus or the N-terminus.

7. A recombinant vector comprising the isolated nucleic acid molecule of claim 1.

8. A method of making a recombinant host cell comprising the isolated nucleic acid molecule of claim 1.

9. A recombinant host cell produced by the method of claim 8.

10. The recombinant host cell of claim 9 comprising vector sequences.

11. An isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence selected from the group consisting of:

(a) a polypeptide fragment of SEQ ID NO:2 or the encoded sequence included in ATCC Deposit No: PTA-2766;

(b) a polypeptide fragment of SEQ ID NO:2 or the encoded sequence included in ATCC Deposit No: PTA-2766, having biological activity;

(c) a polypeptide domain of SEQ ID NO:2 or the encoded sequence included in ATCC Deposit No: PTA-2766;

(d) a polypeptide epitope of SEQ ID NO:2 or the encoded sequence included in ATCC Deposit No: PTA-2766;

5 (e) a full length protein of SEQ ID NO:2 or the encoded sequence included in ATCC Deposit No: PTA-2766;

(f) a variant of SEQ ID NO:2;

(g) an allelic variant of SEQ ID NO:2;

(h) a species homologue of SEQ ID NO:2;

10 (i) a polypeptide comprising amino acids 2 to 330 of SEQ ID NO:2, wherein said amino acids 2 to 330 comprise a polypeptide of SEQ ID NO:2 minus the start methionine;

(j) a polypeptide comprising amino acids 1 to 330 of SEQ ID NO:2; and

(k) a polypeptide encoded by the cDNA contained in ATCC Deposit No.
15 PTA-2766.

12. The isolated polypeptide of claim 11, wherein the full length protein comprises sequential amino acid deletions from either the C-terminus or the N-terminus.

13. An isolated antibody that binds specifically to the isolated polypeptide
20 of claim 11.

14. A recombinant host cell that expresses the isolated polypeptide of claim 11.

15. A method of making an isolated polypeptide comprising:
25 (a) culturing the recombinant host cell of claim 14 under conditions such that said polypeptide is expressed; and

(b) recovering said polypeptide.

16. The polypeptide produced by claim 15.

17. A method for preventing, treating, or ameliorating a medical condition, comprising administering to a mammalian subject a therapeutically effective amount
30 of the polypeptide of claim 11 or the polynucleotide of claim 1.

18. A method of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject comprising:

(a) determining the presence or absence of a mutation in the polynucleotide of claim 1; and

(b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or absence of said mutation.

5 19. A method of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject comprising:

(a) determining the presence or amount of expression of the polypeptide of claim 11 in a biological sample; and

10 (b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or amount of expression of the polypeptide.

 20. A method for identifying a binding partner to the polypeptide of claim 11 comprising:

(a) contacting the polypeptide of claim 11 with a binding partner; and

15 (b) determining whether the binding partner effects an activity of the polypeptide.

 21. The gene corresponding to the cDNA sequence of SEQ ID NO:2.

 22. A method of identifying an activity in a biological assay, wherein the method comprises:

(a) expressing SEQ ID NO:1 in a cell;

20 (b) isolating the supernatant;

(c) detecting an activity in a biological assay; and

(d) identifying the protein in the supernatant having the activity.

 23. The product produced by the method of claim 20.

25 24. A process for making polynucleotide sequences encoding a gene product having altered G-protein coupled receptor activity comprising,

a) shuffling a nucleotide sequence of claim 1;

b) expressing the resulting shuffled nucleotide sequences and,

c) selecting for altered G-protein coupled receptor activity as compared to the G-protein coupled receptor activity of the gene product of said unmodified nucleotide sequence.

30

25. The process of claim 24, wherein the nucleotide sequence is any one of the sequences selected from the group consisting of SEQ ID NO:1, 29, and 54.
26. A shuffled polynucleotide sequence produced from the process of claim 25.
27. An isolated nucleic acid molecule consisting of a polynucleotide having a nucleotide sequence selected from the group consisting of:
- (a) a polynucleotide encoding a polypeptide of SEQ ID NO:2;
 - (b) a polynucleotide comprising nucleotides 518 to 1504 of SEQ ID NO:1, wherein said nucleotides encode a polypeptide of SEQ ID NO:2 minus the start codon;
 - (c) a polynucleotide comprising nucleotides 515 to 1504 of SEQ ID NO:1, wherein said nucleotides encode a polypeptide of SEQ ID NO:2 including the start codon;
 - (d) a polynucleotide encoding the HGPRBMY11 polypeptide encoded by the cDNA clone contained in ATCC Deposit No. PTA-2766;
 - (e) a polynucleotide which represents the complimentary sequence (antisense) of SEQ ID NO:1;
 - (f) a polynucleotide encoding a polypeptide of SEQ ID NO:30;
 - (g) a polynucleotide comprising nucleotides 4 to 1038 of SEQ ID NO:29, wherein said nucleotides encode a polypeptide of SEQ ID NO:30 minus the start codon;
 - (h) a polynucleotide comprising nucleotides 1 to 1038 of SEQ ID NO:29, wherein said nucleotides encode a polypeptide of SEQ ID NO:30 including the start codon;
 - (i) a polynucleotide which represents the complimentary sequence (antisense) of SEQ ID NO:29;
 - (j) a polynucleotide encoding a polypeptide of SEQ ID NO:55;
 - (k) a polynucleotide comprising nucleotides 4 to 1023 of SEQ ID NO:54, wherein said nucleotides encode a polypeptide of SEQ ID NO:55 minus the start codon;

- (l) a polynucleotide comprising nucleotides 1 to 1023 of SEQ ID NO:54, wherein said nucleotides encode a polypeptide of SEQ ID NO:55 including the start codon; and
- (m) a polynucleotide which represents the complimentary sequence (antisense) of SEQ ID NO:54.
28. The isolated nucleic acid molecule of claim 27, wherein the polynucleotide comprises a nucleotide sequence encoding a G-protein coupled receptor protein.
29. The isolated nucleic acid molecule of claim 27, wherein the polynucleotide fragment comprises a nucleotide sequence encoding the polypeptide sequence identified as SEQ ID NO:2, 30, or 55.
30. The isolated nucleic acid molecule of claim 28, wherein the nucleotide sequence comprises sequential nucleotide deletions from either the C-terminus or the N-terminus.
31. A recombinant vector comprising the isolated nucleic acid molecule of claim 28.
32. A recombinant host cell comprising the recombinant vector of claim 31.
33. An isolated polypeptide consisting of an amino acid sequence selected from the group consisting of:
- (a) a polypeptide fragment of SEQ ID NO:2 having G-protein coupled receptor activity;
- (b) a polypeptide domain of SEQ ID NO:2 having G-protein coupled receptor activity;
- (c) a full length protein of SEQ ID NO:2;
- (d) a polypeptide corresponding to amino acids 2 to 330 of SEQ ID NO:2, wherein said amino acids 2 to 330 comprise a polypeptide of SEQ ID NO:2 minus the start methionine;
- (e) a polypeptide corresponding to amino acids 1 to 330 of SEQ ID NO:2;
- (f) a polypeptide encoded by the cDNA contained in ATCC Deposit No. PTA-2766.

- (g) a polypeptide fragment of SEQ ID NO:30 having G-protein coupled receptor activity;
- (h) a polypeptide domain of SEQ ID NO:30 having G-protein coupled receptor activity;
- 5 (i) a full length protein of SEQ ID NO:30;
- (j) a polypeptide corresponding to amino acids 2 to 346 of SEQ ID NO:30, wherein said amino acids 2 to 346 comprise a polypeptide of SEQ ID NO:30 minus the start methionine;
- 10 (k) a polypeptide corresponding to amino acids 1 to 346 of SEQ ID NO:30;
- (l) a polypeptide fragment of SEQ ID NO:55 having G-protein coupled receptor activity;
- (m) a polypeptide domain of SEQ ID NO:55 having G-protein coupled receptor activity;
- 15 (n) a full length protein of SEQ ID NO:55;
- (o) a polypeptide corresponding to amino acids 2 to 341 of SEQ ID NO:55, wherein said amino acids 2 to 341 comprise a polypeptide of SEQ ID NO:55 minus the start methionine; and
- 20 (p) a polypeptide corresponding to amino acids 1 to 341 of SEQ ID NO:55.
34. A method of screening for candidate compounds capable of binding to and/or modulating activity of a G-protein coupled receptor, comprising:
- 25 a.) contacting a test compound with a substantially or partially purified polypeptide according to claim 28; and
- b.) selecting as candidate compounds those test compounds that bind to and/or modulate activity of the polypeptide.
35. The method according to claim 34, wherein the candidate compounds are small molecules.
- 30 36. A cell comprising NFAT/CRE and the polypeptide of claim 11 or 33.

5

37. A cell comprising NFAT G alpha 15 and the polypeptide of claim 11 or 33.

38. A method of screening for candidate compounds capable of modulating activity of a G-protein coupled receptor-encoding polypeptide, comprising:

- (a) contacting a test compound with a cell or tissue expressing the polypeptide according to claim 11 or 33; and
- (b) selecting as candidate modulating compounds those test compounds that modulate activity of the G-protein coupled receptor polypeptide.

10

39. The method according to claim 38, wherein the candidate compounds are agonists or antagonists of G-protein coupled receptor activity.

40. The method according to claim 39, wherein the polypeptide activity is associated with the heart.

15

41. The method according to claim 40, wherein the candidate modulating compounds are peptides.